DELFI Diagnostics to Showcase Whole-Genome cfDNA Platform Advances in Cancer Detection and Monitoring at AACR 2026 Annual Meeting

Five poster presentations span lung cancer early detection, immunotherapy response prediction, cancer subtyping, treatment monitoring, and next-generation sequencing platforms PALO ALTO, Calif., April 6, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based...